Resistance to Proteasome Inhibitors in Cancer

Molecular Mechanisms and Strategies to Overcome Resistance

Nonfiction, Health & Well Being, Medical, Specialties, Oncology, Medical Science, Pharmacology
Cover of the book Resistance to Proteasome Inhibitors in Cancer by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319067520
Publisher: Springer International Publishing Publication: September 16, 2014
Imprint: Springer Language: English
Author:
ISBN: 9783319067520
Publisher: Springer International Publishing
Publication: September 16, 2014
Imprint: Springer
Language: English

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

More books from Springer International Publishing

Cover of the book Filial Obsessions by
Cover of the book Industrial, Trade, and Employment Policies in Iran by
Cover of the book Vocational Education and Training in Times of Economic Crisis by
Cover of the book Intrinsically Disordered Proteins Studied by NMR Spectroscopy by
Cover of the book Financial Crimes: Psychological, Technological, and Ethical Issues by
Cover of the book Mathematical Modeling of Biological Processes by
Cover of the book My 10 Strategies for Integrative Coaching by
Cover of the book Bhagavad Gītā and Leadership by
Cover of the book Speleological and Speleogenetic Aspects of the Monti di Capo San Vito (Sicily) by
Cover of the book Counter-Terrorism from the Obama Administration to President Trump by
Cover of the book Solar Photovoltaic System Applications by
Cover of the book Political Institutions and Democracy in Portugal by
Cover of the book Nanochemistry, Biotechnology, Nanomaterials, and Their Applications by
Cover of the book Proceedings of the Second International Conference on Mechatronics and Automatic Control by
Cover of the book The Future of Leadership - An Explorative Study into Tomorrow's Leadership Challenges by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy